ANTICIPATE-NASH模型对晚期MASLD患者临床事件的危险分层优于组织学
在699例活检证实F3-F4的MASLD患者中,ANTICIPATE-NASH模型对肝脏相关事件(LRE)的区分度(C统计量0.93)高于组织学(0.67),加入组织学未改善预测。结果在1396例临床试验患者中验证,模型区分度0.84优于组织学0.64。
要点
- ANTICIPATE-NASH模型对F3/F4 MASLD患者的LRE风险分层优于组织学分期。
- 组织学分期对模型预测无额外增益,模型校准良好。
- 模型可识别F3中发生LRE风险高和F4中不发生LRE的低风险亚群。
核心结论
- 在F3/F4 MASLD患者中,无创ANTICIPATE-NASH模型对临床事件的危险分层优于组织学分类。
研究设计与样本
- 多中心队列1纳入699例活检证实的F3-F4 MASLD患者,终点为LRE(肝失代偿、肝细胞癌、移植或肝病死亡)。
- 队列2纳入来自4项临床试验的1396例F3-F4患者,采用临床监管终点进行验证。
主要发现
- 队列1中F3与F4分布均等,随访期间发生56例LRE(8.0%),其中51例集中于F4。
- 队列1中ANTICIPATE-NASH模型对LRE的C统计量为0.93,高于组织学的0.67,模型校准优秀。
- 加入组织学未改善模型预测;识别出ANTICIPATE-NASH阈值,高于该值F3患者发生LRE,低于该值F4患者不发生LRE。
- 队列2采用监管终点重现结果,模型C统计量0.84高于组织学的0.64。
临床怎么用
- 对于F3/F4 MASLD患者,可采用ANTICIPATE-NASH模型替代组织学进行临床事件风险分层。
- 该模型有助于临床试验筛选有临床事件风险及肝硬化逆转机会更高的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The reference for risk stratification and clinical trial selection of metabolic dysfunction-associated steatotic liver disease (MASLD) patients is fibrosis degree by histology. The noninvasive ANTICIPATE-NASH models have been validated for risk prediction of clinically significant portal hypertension (CSPH) and liver-related events (LRE). We assessed whether these models provide better risk stratification of events than histology. METHODS: A multicenter cohort 1, including 699 biopsy specimen-proven F3-F4 patients with MASLD was evaluated. The end point was LRE (hepatic decompensation, hepatocellular carcinoma, transplantation, or liver-related death). We assessed (Cox regression) whether histology provided added value to ANTICIPATE-NASH and whether model predictions differed in F3/F4 patients. Results were validated in cohort 2 (1396 F3-F4 patients) from 4 clinical trials using the clinical regulatory end point. RESULTS: In cohort 1, F3 and F4 were equally distributed. There were 56 LREs (8.0%) during follow-up, concentrated in F4 (51 LREs). The ANTICIPATE-NASH model showed excellent discrimination (C statistic, 0.93) for LRE, higher than histology (C statistic, 0.67). Model calibration was excellent. Adding histology did not improve model prediction. Thresholds of ANTICIPATE-NASH above which F3 patients developed LREs and below which F4 patients did not were identified. Results were reproduced in cohort 2 with the regulatory end point, with higher model discrimination (C statistic, 0.84) compared with histology (C statistic, 0.64). CONCLUSIONS: In MASLD patients with F3/F4, the noninvasive ANTICIPATE-NASH models provide better risk stratification of clinical events than histologic classification. These models could be very useful for clinical trials by selecting patients at risk of clinical events and patients with higher chances of observed cirrhosis regression.
引用
- Aceituno L, Bañares J, Pons M, et al. The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease. Gastroenterology. 2025. PMID: 41212130. doi:10.1053/j.gastro.2025.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。